Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 30, 2025BiomedicinesOpen Access

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications

View Full Paper
Ask AI
Bookmark
Share

Authors

WSWojciech SzlasaMKMonika KisielewskaASAnna Sobczyńska-Konefał

Discussion

Loading...

Member takes

Overview

Retrospective study observes improved neutrophil counts with first-line venetoclax-obinutuzumab in chronic lymphocytic leukemia, suggesting better immune recovery than second-line regimens.

Key Points

  • To evaluate the differential impacts of first-line venetoclax-obinutuzumab versus second-line venetoclax-rituximab on immunoglobulin G levels and absolute neutrophil counts in patients with chronic lymphocytic leukemia.
  • Conducted a retrospective observational study of patients diagnosed with chronic lymphocytic leukemia.
  • Compared outcomes between first-line therapy using venetoclax plus obinutuzumab (VenO) and second-line therapy using venetoclax plus rituximab (VenR).
  • Monitored longitudinal changes from baseline in absolute neutrophil counts (ANC) and immunoglobulin G (IgG) concentrations.
  • First-line VenO therapy resulted in a significant improvement in absolute neutrophil count levels relative to baseline.
  • Second-line VenR therapy showed a limited impact on absolute neutrophil counts alongside a decreasing trend in immunoglobulin G levels.
  • Patients receiving second-line VenR had longer disease duration and prior exposure to chemoimmunotherapy, precluding direct statistical equivalence comparisons.

Cite This Study

Szlasa et al. (2025) studied this question.

synapsesocial.com/papers/6a7f68fe1ff2753593c0eaafhttps://doi.org/10.3390/biomedicines13071609
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia2025
  2. 2Comparative safety and efficacy of venetoclax-combination therapies versus obinutuzumab-combination therapies in chronic lymphocytic leukemia: A systematic review and meta-analysis.2026
  3. 3Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab2024 · 4 citations
  4. 4First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025
  5. 5Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia2026